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Does oral alprazolam affect ventilation? a randomised,
double-blind, placebo-controlled trial
Abstract
The respiratory effects of benzodiazepines have been controversial. This investigation aimed to study
the effects of oral alprazolam on ventilation. In a randomised, double-blind cross-over protocol, 20
healthy men ingested 1 mg of alprazolam or placebo in random order, 1 week apart. Ventilation was
unobtrusively monitored by inductance plethysmography along with end-tidal PCO2 and pulse oximetry
60-160 min after drug intake. Subjects were encouraged to keep eyes open. Meanï¿(1/2)+/- was similar
(6.21 +/- 0.71 vs 6.41 +/- 1.12 L/min, P = NS). End-tidal PCO2 and oxygen saturation did also not differ
between treatments. However, coefficients of variation of minute ventilation after alprazolam exceeded
those after placebo (43 +/- 23% vs 31 +/- 13%, P < 0.05). More encouragements to keep eyes open were
required after alprazolam than after placebo (5.2 +/- 5.7 vs 1.3 +/- 2.3 calls, P < 0.05). In a multiple
regression analysis, higher coefficients of variation of minute ventilation after alprazolam were related
to a greater number of calls. Oral alprazolam in a mildly sedative dose has no clinically relevant effect
on ventilation in healthy, awake men. The increased variability of ventilation on alprazolam seems
related to vigilance fluctuations rather than to a direct drug effect on ventilation.
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Abstract 
The respiratory effects of benzodiazepines have been controversial. We therefore 
investigated the effects of alprazolam, an anxiolytic benzodiazepine, on ventilation. In a 
randomized cross-over protocol 20 healthy men (mean age ±SD 28±9y), ingested 1 mg of 
alprazolam or placebo in random order, 1 week apart. Ventilation was unobtrusively 
monitored by inductance plethysmography along with end-tidal carbon dioxide tension, pulse 
oximetry and ECG during 2 periods of 20 minutes starting 40 and 100 min after drug intake. 
Subjects rested supine and were encouraged to keep their eyes open. Minute ventilation 40 
and 100 minutes after alprazolam intake was 6.53±0.87 and 6.21±0.71 L/min, corresponding 
values on placebo were 6.45±1.29 and 6.41±1.12 L/min, P=NS, all instances. End-tidal 
carbon dioxide tension and oxygen saturation did not differ between alprazolam and placebo. 
However, coefficients of variation of minute ventilation were greater during alprazolam than 
during placebo sessions, i.e., 51±41% and 43±23%, vs. 30 ±16% and 31 ±13%, P<0.05. 
Encouragements to keep eyes open were required more frequently during alprazolam than 
during placebo sessions (5.5±5.8 and 5.2±5.7 calls, vs. 1.2±2.7 and 1.3±2.3 calls, P<0.05). In 
a multiple regression analysis the higher coefficients of variation of minute ventilation during 
alprazolam sessions were related to a greater number of calls suggesting a reduced vigilance. 
In conclusion, oral alprazolam in a mildly sedative dose has no clinically relevant effect on 
ventilation in healthy, awake men. The increased variability of ventilation on alprazolam 
seems to derive from vigilance fluctuations rather than from a direct drug effect on 
ventilation. 
Key words: anxiety, drug treatment, side effect, ventilation, apnea, hypoventilation, 
benzodiazepine, alprazolam 
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INTRODUCTION 
Benzodiazepines are widely used for treatment of anxiety and sleep disorders in 
hospitalized patients and outpatients. Nevertheless, their respiratory effects are incompletely 
understood 1. When ingested in high doses or administered intravenously, benzodiazepines 
may induce hypoventilation in normal subjects and in patients with chronic obstructive lung 
disease (COPD) 2-4. In patients with obstructive sleep apnea syndrome (OSA) intravenous 
benzodiazepines may trigger upper airway obstruction with apnea during sleep 5. Conversely, 
clinical experience suggests that relevant respiratory depressant effects of low dose oral 
benzodiazepines are rare. However, there are very few and partly controversial trials to 
support this impression. For example, Mak and colleagues 6 found no reduction of the 
ventilatory response to carbon dioxide in 6 normal subjects after oral midazolam or diazepam 
administration. In 11 and 15 patients with mild to moderate obstructive sleep apnea 7;8 
nitrazepam and temazepam, respectively, did not alter nocturnal oxygen saturation nor induce 
apnea. In 14 patients with mild to moderate hypoxemic, nonhypercapnic COPD oral 
nitrazepam and flunitrazepam did not impair nocturnal oxygenation 9;10 but in 12 awake 
patients with severe COPD oral flunitrazepam slightly reduced minute ventilation and the 
ventilatory response to carbon dioxide 11. Interestingly, Dodson and colleagues 12 found an 
unchanged slope of the ventilatory response to carbon dioxide in 11 healthy subjects after 
ingestion of lorazepam but the position of the response curve was shifted to the left implying 
ventilatory stimulation. Studies in rats 13 and observations in mountaineers at high altitude 14 
and in patients with central sleep apnea  due to heart failure 15 suggested that benzodiazepines 
may decrease the occurrence of central sleep apnea. In summary, studies on respiratory effects 
of orally administered benzodiazepines are scant, have a limited statistical power and have 
provided conflicting results. We therefore performed a randomized, double-blind, placebo 
controlled cross-over study on the respiratory effects of alprazolam, an anxiolytic widely used 
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MAT
Sub
Ass
in clinical practice. The purpose was to evaluate the hypothesis that alprazolam at an 
anxiolytic oral dose would not suppress or even stimulate ventilation in awake healthy 
subjects. To avoid the well known effect of airway instrumentation on breathing pattern and 
ventilation 16 we employed respiratory inductive plethysmography, an unobtrusive technique, 
to monitor ventilation 17. 
 
ERIALS AND METHODS 
jects 
Twenty healthy non-smoking men, mean ±SD age 28 ±9 years, with normal spirometry 
(FEV1 99 ±10 % predicted, FVC 100 ±9 % predicted) were recruited. They had no evidence 
of anxiety disorder (Beck anxiety Inventory, BAI, 4 ± 3) 18. Subjects gave written informed 
consent and the study was approved by the Hospital Ethics Committee. The trial was registred 
at the Swiss Agency for Therapeutic Products (#2005DR2056). 
essments 
A general medical history was obtained. Height, weight, blood pressure, and pulse rate 
were measured. Symptoms of anxiety in the last 30 days were evaluated with the Beck 
Anxiety Inventory (BAI) 18. Anxiety before and during the investigations was monitored 
using the short version of the Spielberger State-Trait-Anxiety Inventory (STAI-K) 19;20 and a 
visual analogue scale (VAS) ranging from completely relaxed (0 mm) to extremely nervous 
(100 mm). Spirometry was performed according to standard techniques 21. 
Ventilation and the patterns were recorded by calibrated respiratory inductive 
plethysmography a technique that accurately monitors lung volume changes without the need 
for instrumentation of the airway 22;23. The inductance plethysmograph (Respitrace PT, Non-
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Invasive Monitoring Systems, Miami Beach, FL, USA) incorporated a pulse oximeter and an 
ECG. The rib cage and abdominal inductance sensors were placed at the level of the nipples 
and the umbilicus, respectively, and secured with tape. The relative gain of their signals was 
determined by the Qualitative Diagnostic Calibration (QDC) method during natural breathing 
24 and the sum of the two signals was calibrated against the integrated output of a flow meter 
22;23. Validation of the calibration at the end of studies revealed a ≤10% deviation of mean 
tidal volume by inductance plethysmography from corresponding flow meter values in all 
instances. End-tidal carbon dioxide concentration (Normocap, Datex-Ohmeda, Helsinki, 
Finnland) derived from the nares, and transcutaneous carbon dioxide tension measured by a 
probe at the volar side of the forearm 25 (Microgas 7650, Kontron Instruments, Schlieren, 
Switzerland) were recorded as surrogates of the arterial PCO2 and calibrated at the beginning 
and end of the recordings. Sampling rate for all signals was 50 Hz. 
tocol 
This was a randomized, double-blind, placebo-controlled, cross-over study. The hospital 
pharmacy prepared sets of 2 identically looking capsules with one containing 1 mg 
alprazolam (Xanax®, Pfizer AG, Zurich, Switzerland) and the other placebo. Each set was 
labeled with a number code that identified the capsule prepared for session one and two, 
respectively. To obtain a balanced design 10 sets contained placebo and 10 alprazolam in the 
capsule for the first session. The code was not broken until completion of data analysis.  
On the study days, subjects were allowed to drink no more than 1 cup of coffee or black 
tee on that morning, but to do the same at both investigation days. At 11 am. they reported to 
the laboratory, completed the anxiety questionnaires and ingested the capsule for the first 
session. Once the monitoring equipment was prepared subjects took place in a comfortable 
supine position on a bed in the sound-proof laboratory. They were instructed to rest quietly 
and keep their eyes open. Measurements started at 11:40 a.m., lasted for 40 min during which 
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subjects watched a documentary video, and were repeated after a 20 min break at 12:40 p.m.. 
Anxiety questionnaires were completed after each measurement period. During the 
measurements subjects were constantly observed by a technician from the adjacent control 
room by a video camera. If the technician had the impression that a subject did not 
concentrate on the video or tended to sink the eye lids she encouraged him to watch the video 
via a microphone-loud-speaker system and recorded the time of the call. 
One week after the first recording session, at the same time of the day, the same protocol 
was repeated after administering the second capsule. 
 
a analysis and statistics 
Breathing pattern variables were determined breath by breath by specialized software 
(RespiEvents, Noninvasive Monitoring Systems, USA) 23. Medians of physiologic variables 
during the final 20 minutes of each recording, i.e. at 12 noon and at 1 p.m., were computed. 
For the group, data from verum and placebo sessions were expressed as means ±SD, and 
compared by paired t-tests. Variances were compared by Levene’s test for equality of 
variance. A probability of <0.05 was considered statistically significant. Based on previous 
studies 23;26 a sample size of >17 subjects was required to detect clinically relevant differences 
in PtcCO2 of 4 mmHg, in SpO2 of 3% and in minute ventilation of 0.6 L/min with a power of 
0.8 (alpha=0.05). 
 
 
RESULTS 
Table 1 summarizes the main outcomes. As expected, alprazolam had a sedative effect as 
demonstrated by the higher number of calls required to draw the subjects’ attention to the 
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video. The anxiety visual analog scores and the STAI-K scores were already very low during 
placebo sessions and no further decrease was noted with alprazolam. 
Neither the mean minute ventilation, nor any other breathing pattern variable were 
altered by alprazolam compared to placebo. In addition, arterial oxygen saturation and 
transcutaneous and end-tidal carbon dioxide tensions remained unchanged as well (table 1). 
However, inspection of individual recordings revealed that the breathing patterns during 
alprazolam were more irregular than during placebo (figure 1). To quantify this irregularity, 
the coefficients of variation (i.e. the SD in percent of the mean value) of breath-by-breath 
breathing pattern variables were computed. The results confirmed a significantly greater 
intra-individual variability of minute ventilation, tidal volume and breath rate with alprazolam 
than with placebo (table 2). A graphical display of the distribution of individual results further 
revealed a greater inter-individual scatter of data during alprazolam compared to placebo 
sessions for minute ventilation, tidal volume and end-tidal carbon dioxide tension (Figure 2). 
To investigate the determinants of the breathing pattern variability, a multiple regression 
analysis was performed with the coefficients of variation of minute ventilation as dependent 
and alprazolam or placebo, vigilance level (represented by the number of encouraging calls 
needed to maintain subjects awake), the first or second measurement period and anxiety level 
(VAS scores at the end of measurement periods) respectively, as independent variables. This 
analysis revealed that the greater variability of minute ventilation during alprazolam sessions 
(Beta = 0.14, P=0.24) was related to a reduced vigilance, i.e. a greater number of encouraging 
calls (Beta = 0.39, P=0.002), even if controlled for the measurement period (Beta = -0.49, 
P=0.63) and the anxiety level (Beta = -0.10, P=0.38). The model explained 21% of the 
variance in the outcome (R = 0.46, SEE=24, P=0.001). 
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DISCUSSION 
We performed a randomized, double-blind, placebo-controlled trial of the respiratory 
effects of alprazolam administered orally in a dose commonly used to treat anxiety in 
outpatients. Alprazolam did not affect mean ventilation, arterial oxygen saturation, carbon 
dioxide tension and heart rate in healthy men although fluctuations in vigilance under the 
influence of alprazolam were associated with an increased variability of ventilation. The 
findings are novel and important since alprazolam is widely used for treatment of anxiety and 
since its respiratory effects have not been rigorously studied. The absence of a clinically 
relevant ventilatory depressant effect of alprazolam is reassuring since it contrasts to some 
reports on other benzodiazepines administered intravenously or in high doses 2. 
Zacharias and coworkers 2 found a transient reduction in mean minute ventilation from 
7.4 L/min to 4.0 L/min lasting for approximately 5 min after intravenous premedication by 
midazolam in 17 male and 17 female otherwise healthy patients undergoing a dental 
treatment. Although arterial oxygen saturation was not significantly altered a potential change 
in alveolar ventilation could not be assessed since arterial PCO2 was not measured. Some 
degree of initial hyperventilation due to anxiety before the dental procedure and a subsequent 
reduction of ventilation to normal or only slightly reduced values under the influence of the 
benzodiazepine could not be ruled out either. Mora and coworkers 27 monitored ventilation by 
a pneumotachograph attached to a facemask during sedation by an intravenous midazolam 
infusion in 16 patients in normal cardiorespiratory health undergoing colonoscopy. Although 
there was a slight increase in the end-tidal carbon dioxide tension over baseline after 
midazolam administration, the values remained well within the normal range, i.e. 42 mmHg at 
the end of the infusion, and minute ventilation and the ventilatory response to CO2 were 
unchanged. Dodson and coworkers 12 observed an unchanged slope of the ventilatory 
response to CO2 in 11 volunteers after oral administration of 1 mg and of 2.5 mg of 
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lorazepam. Interestingly, the position of the CO2 response curve was shifted to the right 
suggesting even a slight ventilatory stimulant action of the benzodiazepine. 
The current investigation helps to resolve the partly contradictory findings from previous 
studies on the respiratory effects of benzodiazepines. By using respiratory inductive 
plethysmography to monitor breathing patterns we were able to avoid the well known 
stimulatory effect of airway instrumentation on ventilation 16. In addition, we estimated 
arterial PCO2 from end-tidal and transcutaneous measurements without the need for an 
arterial puncture or catheterization which might also have stimulated ventilation by the 
associated pain and inconvenience. Even in the absence of such irritation and in slightly 
sedated subjects who had to be encouraged to keep their eyes open we did not observe a 
depressant effect of alprazolam on ventilation and gas exchange. These negative findings are 
well corroborated by the rigorous design of our randomized, placebo controlled and 
appropriately powered study. 
Alprazolam sessions were associated with an increased variability of breath rate, tidal 
volume and minute ventilation (table 2). However, multiple regression analysis revealed, that 
alprazolam was not an independent predictor of an increased variability of the breathing 
pattern when the number of calls to keep the eyes open we taken into account. Therefore, the 
apparent ventilatory destabilizing effect of alprazolam seemed to be related to fluctuations in 
vigilance or arousal state 28 rather than by a direct action of alprazolam on control of 
breathing. The greater between-subject variation of breathing pattern characteristics with 
alprazolam compared to placebo (figure 2) might reflect individual differences in the response 
to the drug. 
The results of our study cannot be extrapolated to patients with severe and hypercapnic 
chronic obstructive pulmonary disease (COPD) in whom oral triazolam and flunitrazepam 
induced a rise in PaCO2 and a fall in minute ventilation 11. In addition, caution with the use of 
benzodiazepines is also warranted in patients with the obstructive sleep apnea syndrome since 
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they might experience an increased tendency to collapse their upper airway 29. Conversely, 
preliminary data indicate that benzodiazepines may have a stabilizing effect on ventilation in 
patients with central sleep apnea 15, and on the periodic breathing with central apneas 
observed in healthy subjects at high altitude 30. 
In conclusion, we found that alprazolam, a drug widely used to treat anxiety in 
outpatients, does not have a clinically relevant effect on ventilation in healthy, awake men 
when administred in an oral dose that induces sedation. 
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Figure Legends 
Figure 1 
Example of a time series of inductive plethysmographic rib cage (RC), and abdominal 
volume signals (AB) along with their sum which corresponds to instantaneous lung volume 
changes (Sum) during placebo-session (top) and alprazolam-session (bottom). Note 
particularly the periodical breathing, which was often observed. Increase of ventilation is 
against to interpret as a seldom effect. Alprazolam was associated with a greater variability of 
breathing patterns than placebo. 
 
Figure 2 
Distribution of individual results (triangles) of end-tidal carbon dioxide partial pressure 
(PetCO2) and breathing pattern variables along with mean values (horizontal lines). During 
alprazolam sessions (Alpr), the scatter of data was significantly greater than during placebo 
sessions (Plac) for PetCO2, minute ventilation, and tidal volume (Levene’s test for equality of 
variance P<0.05). 
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Table 1. Effects of Alprazolam on Ventilation, Breathing Patterns 
and Anxiety 
 Placebo  Alprazolam 
 12 noon 1 p.m. 12 noon 1 p.m. 
Minute ventilation (V’I), L/min 6.53 (0.87) 6.21 (0.71)  6.45 (1.29) 6.41 (1.12) 
Tidal volume (VT), L 0.43 (0.08) 0.40 (0.07)  0.43 (0.12) 0.40 (0.10) 
Breath rate, breaths/min 15.8 (2.5) 16.2 (2.6)  15.8 (2.4) 16.5 (3.3) 
Duty cycle (TI/TT) 0.41 (0.03) 0.41 (0.04)  0.42 (0.03) 0.42 (0.04) 
VT/TI, ml/seconds 247 (97) 236 (91)  253 (83) 252 (78) 
Apneas/hypopneas (events/20 min) 0.40 (0.99) 0.30 (0.66)  0.80 (2.35) 1.20 (3.14) 
SpO2, % 97.6 (1.00) 97.7 (0.81)  97.6 (1.35) 97.5 (0.88) 
PtcCO2, mmHg 46 (2) 48 (4)  46 (4) 48 (6) 
PetCO2, mmHg 45 (2) 44 (3)  45 (4) 45 (5) 
Heart rate, beats/min 62.4 (8.4) 61.7 (8.9)  64.9 (10.4) 64.0 (11.0) 
Vigilance (calls during 20min) 1.2 (2.7) 1.3 (2.3)  5.5 (5.8) * 5.2 (5.7) * 
Anxiety – VAS 12 (8) 12 (11)  9 (9) 12 (12) 
Anxiety – State Anxiety inventory 8.5 (2.0) 8.0 (1.9)  8.1 (2.9) 8.2 (2.2) 
Means ±SD, n=20; VT/TI: mean inspiratory flow; SpO2: oxygen saturation by pulse oximetry; 
PtcCO2, and PetCO2: transcutaneous and end-tidal CO2 tension; VAS: visual analog scale ranging 
from 0 to 100 mm. * P<0.05 vs. placebo; 
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Table 2. Variability of Ventilation During Alprazolam and 
Placebo Sessions 
 Placebo Alprazolam 
 12 noon 1 p.m. 12 noon 1 p.m. 
CV minute ventilation (V’I), % 30 (16) 31 (13) 51 (41)* 43 (23)* 
CV tidal volume (VT), % 34 (20) 35 (17) 41 (21)* 42 (19)* 
CV breath rate, % 18 (8) 18 (8) 25 (15)* 24 (15)* 
N=20; values are mean (SD) coefficients of variation (CV = SD/mean, percent) for within 
subjects variability during the measurement periods; * P<0.05 vs. corresponding value on 
placebo 
 
 
 
 
 
